StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 54.3 %

GLMD opened at $6.90 on Friday. Galmed Pharmaceuticals has a 12 month low of $2.73 and a 12 month high of $23.80. The business’s 50-day moving average price is $3.90 and its 200-day moving average price is $4.14. The company has a market cap of $34.81 million, a P/E ratio of -2.88 and a beta of 0.67.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.